Table 3.
Comparative analysis between children exposed to different protease inhibitors at CAISM/UNICAMP from 2000 to 2015
| Variables | ATV | NFV | LPV/R | p* | ATV x LPV/R | NFV x LPV/R | ATV x NFV | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | RR | CI 95% | RR | CI 95% | RR | CI 95% | ||
| Gestational age (weeks) | |||||||||||||
| <34 weeks | 0 | 0 | 4 | 3.1 | 11 | 2.7 | 0.0922 | NC | 0.71 | 0.47–1.07 | NC | ||
| >=34 weeks | 25 | 100 | 126 | 96.9 | 402 | 97.3 | 1.00 | ||||||
| Gestational age (Capurro) | |||||||||||||
| <37 weeks | 6 | 24 | 22 | 16.9 | 99 | 24 | 0.0922 | 1.00 | 0.41–2.44 | 0.71 | 0.47–1.07 | 1.43 | 0.63–3.26 |
| >=37 weeks | 19 | 76 | 108 | 83.1 | 314 | 76 | 1.00 | 1.00 | 1.00 | ||||
| Birth weight | |||||||||||||
| <2500 g | 5 | 19.2 | 24 | 18.2 | 104 | 24.6 | 0.1242 | 0.74 | 0.29–1.92 | 0.74 | 0.50–1.10 | 1.06 | 0.44–2.57 |
| >=2500 g | 21 | 80.8 | 108 | 81.8 | 318 | 75.4 | 1.00 | 1.00 | 1.00 | ||||
| Birth weight | |||||||||||||
| <1500 g | 0 | 0 | 8 | 6.1 | 13 | 3.1 | 0.023 | NC | 1.5 | 0.85–2.65 | NC | ||
| 1500 g - 2499 g | 5 | 19.2 | 16 | 12.1 | 91 | 21.6 | 0.59 | 0.36–0.95 | 1.46 | 0.62–3.45 | |||
| >=2500 g | 21 | 80.8 | 108 | 81.8 | 318 | 75.4 | 1.5 | 1.00 | |||||
| Weight adequacy for GA | |||||||||||||
| Adequate for GA | 19 | 76 | 110 | 83.3 | 312 | 75.4 | 0.0004 | 1.00 | 1.00 | 1.00 | |||
| Small for GA | 5 | 20 | 15 | 11.4 | 97 | 23.4 | 0.85 | 0.33–2.23 | 0.51 | 0.31–0.85 | 1.7 | 0.71–4.03 | |
| Large for GA | 1 | 4 | 7 | 5.3 | 5 | 1.2 | 2.90 | 0.46–18.31 | 2.24 | 1.34–3.71 | 0.85 | 0.13–5.56 | |
| 5th minute Apgar | |||||||||||||
| <7 | 0 | 0 | 1 | 0.8 | 2 | 0.5 | 0.5603** | 1.4 | 0.28–6.97 | ||||
| >=7 | 25 | 100 | 131 | 99.2 | 418 | 99.5 | 1.00 | ||||||
| Neonatal disease | |||||||||||||
| Yes | 8 | 30.8 | 27 | 21.3 | 122 | 29.4 | 0.0723 | 1.06 | 0.47–2.38 | 0.71 | 0.49–1.04 | 1.5 | 0.71–3.15 |
| No | 18 | 69.2 | 100 | 78.7 | 293 | 70.6 | 1.00 | 1.00 | 1.00 | ||||
| Birth defect | |||||||||||||
| Yes | 1 | 3.8 | 16 | 12.1 | 43 | 10.1 | 0.5135 | 0.37 | 0.05–2.67 | 1.16 | 0.74–1.82 | 0.33 | 0.05–2.30 |
| No | 25 | 96.2 | 116 | 87.9 | 382 | 89.9 | 1.00 | 1.00 | 1.00 | ||||
| Anemia | |||||||||||||
| Yes | 2 | 8.3 | 33 | 27.5 | 92 | 23.1 | 0.3183 | 0.32 | 0.08–1.33 | 1.2 | 0.85–1.69 | 0.28 | 0.07–1.14 |
| No | 22 | 91.7 | 87 | 72.5 | 307 | 76.9 | 1.00 | 1.00 | 1.00 | ||||
| Thrombocytopenia | |||||||||||||
| Yes | 3 | 12.0 | 6 | 5.0 | 13 | 3.3 | 0.0755 | 3.49 | 1.16–10.45 | 1.4 | 0.71–2.76 | 2.05 | 0.75–5.56 |
| No | 22 | 88.0 | 113 | 95.0 | 387 | 96.8 | 1.00 | 1.00 | 1.00 | ||||
| Hepatic changes | |||||||||||||
| Yes | 5 | 25.0 | 28 | 90.3 | 63 | 24.1 | < 0.0001 | 1.04 | 0.39–2.77 | 20.62 | 6.43–66.07 | 0.18 | 0.08–0.42 |
| No | 15 | 75.0 | 3 | 9.7 | 198 | 75.9 | 1.00 | 1.00 | 1.00 | ||||
| TOTAL | 26 | 132 | 425 | ||||||||||
GA gestacional age, ATV atazanavir, NFV nelfinavir, LPV lopinavir, R ritonavir
(#) Numbers are different due to the lack of information on some patients
(# #) Not calculated
*Chi-square, **Fisher Exact